Quantedge Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Quantedge Capital’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,500	Closed	-$264K	–	50
2026 Q1	$264K	Sell	13,500 -78,200	-85%	-$1.91M	0.14%	45
2025 Q4	$2.46M	Buy	91,700 +46,600	+103%	+$1.2M	1.17%	22
2025 Q3	$1.2M	Buy	+45,100	New	+$1.16M	0.66%	29
2023 Q4	–	Sell	-36,389	Closed	-$1.67M	–	110
2023 Q3	$1.67M	Buy	36,389 +5,300	+17%	+$289K	0.91%	36
2023 Q2	$1.79M	Buy	31,089 +24,700	+387%	+$1.09M	0.8%	40
2023 Q1	$240K	Sell	6,389 -28,764	-82%	-$943K	0.09%	116
2022 Q4	$985K	Sell	35,153 -71,047	-67%	-$2.06M	0.33%	81
2022 Q3	$2.98M	Sell	106,200 -15,300	-13%	-$500K	0.92%	37
2022 Q2	$4.23M	Buy	121,500 +90,400	+291%	+$3.23M	0.85%	39
2022 Q1	$1.12M	Buy	+31,100	New	+$882K	0.33%	83

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quantedge Capital's AMPH Position: Q2 2026 in Review

Quantedge Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 13,500 shares — an estimated $264K sold.

Quantedge Capital first reported a position in AMPH in Q1 2022 and held it in 10 quarters. The position peaked at $4.23M in Q2 2022. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

Quantedge Capital reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quantedge Capital sold 13,500 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $264K.
Quantedge Capital first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 10 quarters.
Quantedge Capital's Amphastar Pharmaceuticals position peaked at $4.23M in Q2 2022.
212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Quantedge Capital's 13F filing for Q2 2026, filed 6 Aug 2026.